Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer

被引：27
|
作者：
Choughule, A. [1 ]
Sharma, R. [1 ,2 ]
Trivedi, V. [1 ,2 ]
Thavamani, A. [1 ,2 ]
Noronha, V. [1 ]
Joshi, A. [1 ]
Desai, S. [3 ]
Chandrani, P. [2 ]
Sundaram, P. [2 ]
Utture, S. [1 ]
Jambhekar, N. [3 ]
Gupta, S. [1 ]
Aich, J. [2 ]
Prabhash, K. [1 ]
Dutt, A. [2 ]
机构：
[1] Tata Mem Hosp, Tata Mem Ctr, Dept Med Oncol, Bombay 400012, Maharashtra, India
[2] Tata Mem Hosp, Adv Ctr Treatment Res & Educ Canc, Navi Mumbai, India
[3] Tata Mem Hosp, Tata Mem Ctr, Dept Pathol, Bombay 400012, Maharashtra, India
来源：
BRITISH JOURNAL OF CANCER | 2014年 / 111卷 / 11期
基金：
英国惠康基金;
关键词：
GROWTH-FACTOR-RECEPTOR; GEFITINIB; THERAPY; GENE; ERLOTINIB; SURVIVAL; FEATURES;
D O I：
10.1038/bjc.2014.401
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2203 / 2204
页数：4
相关论文
共 50 条
  • [31] Wild-Type KRAS Mediates Growth Inhibition and Resistance to MEK Inhibitors through Dimerization with Mutant KRAS in Lung Adenocarcinoma
    Ambrogio, C.
    Kohler, J.
    Zhou, Z.
    Wang, H.
    Paranal, R.
    Capelletti, M.
    Caffarra, C.
    Li, S.
    Lv, Q.
    Gondi, S.
    Hunter, J.
    Chiarle, R.
    Santamaria, D.
    Westover, K.
    Janne, P.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2261 - S2261
  • [32] Wild-type KRAS mediates growth inhibition and resistance to MEK inhibitors through dimerization with mutant KRAS in lung adenocarcinoma
    Ambrogio, C.
    Kohler, J.
    Zhou, Z.
    Wang, H.
    Paranal, R.
    Capelletti, M.
    Caffarra, C.
    Li, S.
    Lv, Q.
    Santamaria, D.
    Westover, K. D.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [33] Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
    Baldelli, Elisa
    El Gazzah, Emna
    Moran, John Conor
    Hodge, Kimberley A.
    Manojlovic, Zarko
    Bassiouni, Rania
    Carpten, John D.
    Ludovini, Vienna
    Baglivo, Sara
    Crino, Lucio
    Bianconi, Fortunato
    Dong, Ting
    Loffredo, Jeremy
    Petricoin, Emanuel F.
    Pierobon, Mariaelena
    GENES, 2021, 12 (09)
  • [34] EGFR mutant status and tyrosine-kinase inhibitors affect the GKRS outcomes for NSCLC brain metastases
    Liao, Hung-Ruei
    Chiang, Chi-Lu
    Shen, Chia-, I
    Chen, Ching-Jen
    Yang, Huai-Che
    Wu, Hsiu-Mei
    Luo, Yung-Hung
    Hu, Yong-Sin
    Lin, Chung-Jung
    Chung, Wen-Yuh
    Shiau, Cheng-Ying
    Guo, Wan-Yuo
    Pan, David Hung-Chi
    Lee, Cheng-Chia
    JOURNAL OF NEURO-ONCOLOGY, 2022, 159 (03) : 675 - 684
  • [35] Sensitization of EGFR Wild-Type Non-Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor Erlotinib
    Raimbourg, Judith
    Joalland, Marie-Pierre
    Cabart, Mathilde
    de Plater, Ludmilla
    Bouquet, Fanny
    Savina, Ariel
    Decaudin, Didier
    Bennouna, Jaafar
    Vallette, Francois M.
    Lalier, Lisenn
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (08) : 1634 - 1644
  • [36] Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer
    Carter, C. A.
    Rajan, A.
    Keen, C.
    Szabo, E.
    Khozin, S.
    Thomas, A.
    Brzezniak, C.
    Guha, U.
    Doyle, L. A.
    Steinberg, S. M.
    Xi, L.
    Raffeld, M.
    Tomita, Y.
    Lee, M. J.
    Lee, S.
    Trepel, J. B.
    Reckamp, K. L.
    Koehler, S.
    Gitlitz, B.
    Salgia, R.
    Gandara, D.
    Vokes, E.
    Giaccone, G.
    ANNALS OF ONCOLOGY, 2016, 27 (04) : 693 - 699
  • [37] Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers
    Offin, Michael
    Rizvi, Hira
    Tenet, Megan
    Ni, Andy
    Sanchez-Vega, Francisco
    Li, Bob T.
    Drilon, Alexander
    Kris, Mark G.
    Rudin, Charles M.
    Schultz, Nikolaus
    Arcila, Maria E.
    Ladanyi, Marc
    Riely, Gregory J.
    Yu, Helena
    Hellmann, Matthew D.
    CLINICAL CANCER RESEARCH, 2019, 25 (03) : 1063 - 1069
  • [38] EGFR mutant status and tyrosine-kinase inhibitors affect the GKRS outcomes for NSCLC brain metastases
    Hung-Ruei Liao
    Chi-Lu Chiang
    Chia-I. Shen
    Ching-Jen Chen
    Huai-Che Yang
    Hsiu-Mei Wu
    Yung-Hung Luo
    Yong-Sin Hu
    Chung-Jung Lin
    Wen-Yuh Chung
    Cheng-Ying Shiau
    Wan-Yuo Guo
    David Hung-Chi Pan
    Cheng-Chia Lee
    Journal of Neuro-Oncology, 2022, 159 : 675 - 684
  • [39] BIM EXPRESSION IN EGFR-MUTANT LUNG CANCER 3D SPHEROIDS PREDICTS RESPONSIVENESS TO TYROSINE KINASE INHIBITORS
    Lee, Hyun-Kyung
    Barbone, Dario
    Bivona, Trever
    Broaddus, V. C.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1068 - S1069
  • [40] Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR
    Mitsuoka, Shigeki
    Kawaguchi, Tomoya
    Kubo, Akihito
    Isa, Shun-ichi
    Asai, Kazuhisa
    Uji, Masato
    Watanabe, Tetsuya
    Sawa, Kenji
    Yoshimoto, Naoki
    Oka, Takako
    Nakai, Toshiyuki
    Suzumura, Tomohiro
    Tanaka, Hidenori
    Matsuura, Kuniomi
    Kimura, Tatsuo
    Yoshimura, Naruo
    Kudoh, Shinzoh
    Hirata, Kazuto
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (02) : 193 - 203
12345